Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity

11 Jul 2024 07:01 CEST

Subscribe
Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1269689_2024_07_11_PR_OBA_IND_Approval.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Attachments

  • Original Link
  • Permalink

Disclaimer

Biophytis SA published this content on 11 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2024 05:08:06 UTC.